In patients with cancer types seldom presenting the G12C mutation, like PDAC and CRC, where these mutations represent less than 1.5% and 7% of all KRAS mutations, respectively, sotorasib has also shown some promising clinical activity. This evidence concerns the gene KRAS and colorectal carcinoma.